ArticleCurrent microbiology2025
Ceftazidime Combined with Bifico Improves Therapeutic Efficacy and Intestinal Safety in a Mouse Model of Pseudomonas aeruginosa Pneumonia.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial pneumonia is a serious infectious disease with high morbidity and mortality, particularly in elderly and immunocompromised individuals. Ceftazidime is a first-line treatment, but its use is limited by adverse effects on gut health. In a murine model of Pseudomonas aeruginosa pneumonia, we evaluated the efficacy and intestinal safety of combining Ceftazidime with Bifico. The results revealed that, Bifico alone showed limited therapeutic efficacy against Pseudomonas aeruginosa-induced bacterial pneumonia, whereas its combination with Ceftazidime significantly enhanced treatment outcomes, particular in reducing lung injury scores (Ceftazidime-Bifico combination treatment: mean ± SD = 1.42 ± 0.23 vs. Ceftazidime treatment: mean ± SD = 1.94 ± 0.53, p < 0.05). While Bifico alone exerted weak anti-inflammatory effects, its combination with Ceftazidime produced significantly stronger anti-inflammatory effects than Ceftazidime alone (p < 0.05). Notably, Ceftazidime-induced gut dysbiosis was alleviated by Bifico, which mitigated intestinal inflammation and restored microbial diversity, as reflected by a Chao index comparable to control and higher than Ceftazidime alone (Ceftazidime-Bifico combination treatment: mean ± SD = 482.22 ± 73.21 vs. Ceftazidime treatment: mean ± SD = 349.64 ± 61.14, p < 0.05). These findings indicate that the Ceftazidime-Bifico combination enhances therapeutic efficacy while preserving gut homeostasis, representing a promising and safer strategy for managing bacterial pneumonia.
Indexed as
Identifiers
41369884What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.